« Technology And Positive Attitudes Improving Older People’s Lives
Constipation in the acutely hospitalized older patients »

Allon’s Phase 1 Trial Broadens Davunetide’s Intranasal Safety And Dose Range

March 12th, 2010 by admin

Zoloft Children Overdose Blood Pressure Meds And Viagra Does Paxil And Dexatrim Max Interact Prednisone Damage Heart Cipro Ear Drops Use In Dogs Medicamento Nexium Can Lamictal Cause Tremors Sulfur Antabuse Is Hgh Sold In Stores Soma Safe Bed Meloxicam Tbts Mobic Augmentin 875-125 Dosage All Natura Viagra Omnicef Induced Fever Pregnancy And Dilantin Transsexual Breast Augmentation Desyrel 50mg Effexor And Relax Ventolin Evohaler Clomid Testicular Axis Allegra Lead Investigator Prednisone High Dose Long Term How Good Is Fosamax Maximum Dose Of Aricept Paxil Lawsuits Delaware Norvasc Adverse Effects Osteoarthritis Paxil Viagra Online Ordering Flomax Generic Name Flonase Leukopenia Dilantin Blood Level Ultram Picture Thunderbird Samaritan Coumadin Clinic Allergic To Prozac Artist Michael Soma Differin Mall Toronto Synthroid And Calcium Statistics Of Weight Gain On Paxil Lexapro Image Breast Enhancement Archive Zocor Pros Cons Conditions Sinequan Can Be Prescribed For Active Ingredients In Motrin Arimidex Men Excess Estrogen Osteoporosis Adhd Lexapro Effexor Prilosec United Kingdom Drug Interactions With Prozac Natural Viagra China Prednisone Azathioprine Weaning Off Of Prozac And Pregnancy

Allon Therapeutics Inc. (TSX:NPC) announced today that a Phase 1 clinical trial of its lead neuroprotective drug, davunetide , which began patient enrolment January 28, 2010, has been completed. The results demonstrated that the intranasal dose range can be broadened and provided additional information on the pharmacokinetic profile of davunetide…

More: continued here

This entry was posted on Friday, March 12th, 2010 at 11:03 pm and is filed under Alzheimer's Disease. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply